TALZENNA 0.25 MG
TALAZOPARIB (TALAZOPARIB TOSYLATE) : 0.25 MG · DIN 02492032 · PFIZER CANADA ULC
Health Canada status: MARKETED
What is TALZENNA?
TALZENNA 0.25 MG contains TALAZOPARIB (TALAZOPARIB TOSYLATE) : 0.25 MG. It is listed in the Health Canada Drug Product Database under DIN 02492032, held by PFIZER CANADA ULC, supplied as CAPSULE for ORAL administration. Health Canada currently lists it as marketed, status dated 16-May-2025. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is TALZENNA used for?
Monotherapy for gBRCAm HER2-negative locally advanced or metastatic breast cancer. In combination with enzalutamide for HRR gene-mutated metastatic castration-resistant prostate cancer (mCRPC).
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
Product details and regulatory record
| DIN | 02492032 |
|---|---|
| Brand name | TALZENNA |
| Generic / active ingredient | TALAZOPARIB (TALAZOPARIB TOSYLATE) : 0.25 MG |
| Manufacturer | PFIZER CANADA ULC |
| Strength | 0.25 MG |
| Dosage form | CAPSULE |
| Route of administration | ORAL |
| Schedule | Prescription |
| ATC code | L01XK04 TALAZOPARIB |
| AHFS class | 10:00.00 |
| Biosimilar | No |
| Health Canada status | MARKETED |
| Status date | 16-May-2025 |
| Original market date | 2025-05-16 00:00:00 |
How is it administered?
Breast cancer: 1 mg orally once daily. mCRPC: 0.5 mg orally once daily in combination with enzalutamide 160 mg. Swallow whole; do not crush/chew. Take with or without food.
Included because it drives pack selection and wastage. Consult the monograph.
How is it stored and handled?
Not specified in the provided text (refer to section 11).
How is it supplied?
Not explicitly detailed in provided text beyond capsule descriptions (0.1 mg, 0.25 mg, 0.35 mg, 0.5 mg, 1 mg).
Contraindications
Hypersensitivity to this drug or to any ingredient in the formulation, including any non-medicinal ingredient, or component of the container.
Warnings and precautions
Serious risks: Myelodysplastic Syndrome/Acute Myeloid Leukemia (MDS/AML), myelosuppression (anemia, neutropenia, thrombocytopenia), and fetal harm. Monitor CBC monthly for first 12 months.
What can be used instead?
Other Canadian products sharing ATC code L01XK04 TALAZOPARIB. 2 of 5 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| TALZENNA | 0.1 MG | CAPSULE | PFIZER CANADA ULC | MARKETED | DIN 02555050 |
| TALZENNA | 0.35 MG | CAPSULE | PFIZER CANADA ULC | APPROVED | DIN 02555069 |
| TALZENNA | 0.5 MG | CAPSULE | PFIZER CANADA ULC | APPROVED | DIN 02555077 |
| TALZENNA | 1 MG | CAPSULE | PFIZER CANADA ULC | APPROVED | DIN 02492040 |
Who else supplies TALAZOPARIB worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. TALAZOPARIB appears in 23 registered pack listings across 9 markets, published on 8 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.